How to Use Mishale

Mishale turns one question — a disease and a candidate gene — into a structured feasibility memo you can act on. From a single input it assembles target rationale, guide or transgene design, off-target risk, delivery, dosing, and regulatory pathway from public data, in under a day.

1 · Create your account

Sign in at mishale.bio with a one-time email link — no password to manage. Every account starts with 3 free reports, so you can evaluate a target before buying anything.

2 · Run a feasibility memo

Open the Design Studio and describe your intent in plain language: the disease and, where you have one, the gene. Naming the gene removes ambiguity for diseases with more than one cause. For example:

sickle cell disease BCL11A
haemophilia B F9
Leber congenital amaurosis RPE65

Submit, and the engine resolves the target, selects an editing or replacement strategy, and assembles the memo. Each run consumes one credit.

3 · Read your memo

Every memo opens with a feasibility verdict — feasible, feasible with caveats, or not recommended as designed — listing any blockers and caveats up front. Below it are six sections:

Target Rationale

Mechanism class, inheritance, therapeutic-modality fit, and a target-confidence score, assessed against the knowledge base and approved-therapy precedents.

Guide / Transgene Design

For editing strategies, ranked guide RNAs with efficiency and specificity scores. For gene replacement, a transgene cassette with a single-AAV (~4.7 kb) cargo-fit check.

Off-Target Screen

Candidate off-target sites screened against the reference genome and tiered HIGH / MEDIUM / LOW by consequence, flagging where wet-lab confirmation is warranted.

Vector Recommendation

A delivery vector matched to the target tissue, with a payload-size check.

Dosing Rationale

An indicative dose range derived from approved-product precedent, with the relevant safety ceiling.

Regulatory Pathway

An FDA/EMA risk tier, the genotoxicity and biodistribution questions to expect, a likely preclinical study list, and a CMC checklist.

Every finding is traceable to a public-data source and carries a confidence score with its limitations stated. You receive the memo as a PDF and a machine-readable data file.

4 · What it will and won’t answer

Mishale designs monogenic targets. For polygenic or complex diseases — a generic query such as “hypertension” — it declines rather than guess, which is intended behaviour. If a target falls outside its current coverage it says so rather than fabricate a design. A clear “no” or “not yet” is part of the answer.

5 · Credits & billing

Reports run on credits. After your three free reports, buy a pack on the Pricing page (1, 3, or 10 reports); credits never expire. Teams running many targets can move to Growth or Enterprise terms — talk to us.

6 · Scope

A memo is a computational feasibility study from public data — a go/no-go decision aid, not an IND-enabling package or a wet-lab result. Confirm every finding experimentally before acting on it.

Get help

Product questions: support@mishale.bio. Anything else: contact@mishale.bio.